7/102 sources · 2 publishersUpdated Oct 25, 10:50 UTC
Regeneron reports nearly four‑year data showing 37% lower death risk with adjuvant Libtayo in high‑risk CSCC
Regeneron presented long‑term results from the Phase 3 C‑POST trial at the ESMO 2026 meeting. After a median follow‑up of 44 months, adjuvant Libtayo reduced overall‑survival risk by 37% versus placebo in patients with high‑risk cutaneous squamous cell carcinoma. The benefit persisted regardless of baseline minimal residual disease status, and safety remained comparable to earlier reports.
Why it matters
The company says the emerging overall‑survival advantage supports using Libtayo immediately after surgery and radiation rather than waiting for recurrence, potentially expanding its market share in the adjuvant CSCC space.
Key facts
- 1The trial enrolled 415 patients, with 209 assigned to Libtayo and 206 to placebo. stocktitan.net
- 2Median follow‑up was 44 months. quiverquant.com
- 3Overall‑survival risk reduction was 37% (hazard ratio 0.63; 95% CI 0.36‑1.11). quiverquant.com
- 4Patients who were MRD‑negative at baseline still showed improved disease‑free survival (HR 0.45; 95% CI 0.22‑0.95). quiverquant.com
- 588% of placebo patients who experienced recurrence crossed over to receive Libtayo (61 of 69). quiverquant.com
- 6Treatment‑emergent adverse events of any grade occurred in 94% of Libtayo patients and 91% of placebo patients. quiverquant.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.